{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-016715","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.005654+00:00","generated_at":"2026-06-05T16:08:25.850141+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emmaus Life Sciences exchanges $9M maturing notes for new 10% notes due 2025; conversion price adjustable","bullets":["Exchanged $9M principal of 2% convertible notes due Feb 24, 2024 for new 10% notes due Feb 24, 2025.","Conversion price initially $0.13/share, subject to quarterly decrease to equal VWAP; no additional consideration.","Principal and interest on new notes payable in two equal semi-annual installments.","Note holders joined Transfer Restriction and Voting Agreement, restricting resale and voting of conversion shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-016715","json":"https://secwatch.observer/filing/0001213900-24-016715.json","markdown":"https://secwatch.observer/filing/0001213900-24-016715.md","text":"https://secwatch.observer/filing/0001213900-24-016715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/0001213900-24-016715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/ea0200618-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:08:25.850141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87166969c00b9ccb3fbd6e28a2204a9d0733cad2","claim":"Emmaus Life Sciences, Inc. amended convertible notes of $9 million with note holders at 10% per annum, payable semi-annually maturing February 24, 2025.","evidence_excerpt":"On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/0001213900-24-016715-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$9 million"},{"label":"Counterparty","value":"note holders"},{"label":"Rate","value":"10% per annum, payable semi-annually"},{"label":"Maturity","value":"February 24, 2025"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"03ed0685cf8c4996d2d10dc2d65731be9db259d9","claim":"Emmaus Life Sciences, Inc. entered into Exchange Agreement with note holders valued at $9 million principal amount of convertible promissory notes (effective 2024-02-21).","evidence_excerpt":"On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/0001213900-24-016715-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"note holders"},{"label":"Value","value":"$9 million principal amount of convertible promissory notes"},{"label":"Effective","value":"2024-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}